// App-Quantinova.ai

BSH2020‐PO‐051 : Second primary malignancies in patients receiving treatment with ruxolitinib for myelofibrosis – a regional experience

Researchers

Presenter

  • J. Schofield

Principal Investigators

  • R. Wells

  • T. Nicholson

  • N. M. Butt

Medical Centers

  • Department of Haematology, Clatterbridge Cancer Centre

  • Department of Haematology, Whiston Hospital, Prescot, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Myeloid neoplasms

  • Alpha-thalassemia myelodysplasia syndrome

  • Squamous cell carcinoma

  • Bladder Cancer

  • B cell lymphomas

  • Lung Cancer

  • Myelofibrosis

  • Breast cancer

  • Solid malignancies

  • Melanoma

  • Lymphomas

Biomarkers

  • Janus kinase

  • Serpin B3

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved